Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1215-1218, 2003; 10.1373/49.7.1215
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gazzolo, D.
Right arrow Articles by Michetti, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gazzolo, D.
Right arrow Articles by Michetti, F.
Related Collections
Right arrow Pediatric Clinical Chemistry
Right arrow Proteomics and Protein Markers
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2003;49:1215-1218.)
© 2003 American Association for Clinical Chemistry, Inc.

Technical Briefs

Maternal Glucocorticoid Supplementation and S100B Protein Concentrations in Cord Blood and Urine of Preterm Infants

Diego Gazzolo1, Maria Kornacka2, Matteo Bruschettini1, Mario Lituania1, Lia Giovannini1, Giovanni Serra1, Urszula Majewska2 and Fabrizio Michetti3,a

1 Department of Pediatrics and Obstetrics, G Gaslini Children’s University Hospital, I-16167 Genoa, Italy

2 Department of Neonatology, Warsaw Medical University Hospital, P-00315 Warsaw, Poland

3 Institute of Anatomy and Cell Biology, Catholic University, Largo Francesco Vito, 1, I-00168 Rome, Italy

aauthor for correspondence: fax 39-0630154813, e-mail fabrizio.michetti@rm.unicatt.it

The first 300 words of the full text of this article appear below.

Maternal glucocorticoid (GC) supplementation is widely used for the prevention of lung immaturity (1)(2), but its possible harmful effects on other organs, including the central nervous system (CNS), are still a matter of debate (3)(4)(5)(6)(7)(8)(9).

S100B, which is present mainly in the nervous system (10) and has a short half-life (11), is regarded as a useful marker of brain injury, although at physiologic concentrations it may act as a cytokine with a neurotrophic effect (10)(12)(13)(14)(15)(16)(17)(18)(19). S100B concentrations in cord blood or urine have already been used to monitor brain distress on the fetal/newborn CNS (15)(17)(18)(19)(20)(21).

We investigated the possible effects of maternal GC administration on the CNS of newborns by measuring S100B in cord blood and longitudinally in urine. Between April 2000 and June 2002, we measured S100B in the umbilical cord blood and urine of infants, born at our tertiary referral centers for obstetric care, who were admitted to the neonatal intensive care units (NICUs) of our hospitals. From our database we retrieved the 39 infants whose mothers had been treated antenatally with corticosteroids and matched them for gestational age at recording with 39 infants whose mothers had not been treated with steroids (1 control for each patient in the GC group). Exclusion criteria included multiple pregnancies, fetal/neonatal cardiac or hemolytic diseases, fetal malformations, and chromosomal abnormalities.

The mothers in the GC group had received betamethasone (12 mg intravenously for 2 days) when spontaneous or planned preterm delivery was expected to occur. The main complications in the . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.